Pharmacological targeting of eIF4E in primary CLL lymphocytes

Blood Cancer Journal

Volumn 3, Issue 9, 2013, Pages

  Martinez Marignac, V ^a   Shawi, M ^a   Pinedo Carpio, E ^a   Wang, X ^a   Panasci, L ^a   Miller, W ^a   Pettersson, F ^a   Aloyz, R ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; INITIATION FACTOR 4E; PROTEIN KINASE B; RIBAVIRIN;

CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG SENSITIZATION; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; IC 50; LETTER; LYMPHOCYTE; PROTEIN PHOSPHORYLATION;

EID: 84885350478     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.43     Document Type: Letter

References (16)

1. Sonenberg N, Gingras AC. The mRNA 50 cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998; 10: 268-275. (Pubitemid 28174770)
2. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337. (Pubitemid 38418805)
3. Strudwick S, Borden KL. The emerging roles of translation factor eIF4E in the nucleus. Differentiation 2002; 70: 10-22. (Pubitemid 38232695)
4. Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia 2011; 25: 1197-1200.
5. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68: 631-634. (Pubitemid 351206735)
6. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 2004; 101: 18105-18110. (Pubitemid 40054081)
7. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015-1027. (Pubitemid 34618840)
8. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proofof- principle clinical trial with ribavirin. Blood 2009; 114: 257-260.
9. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 2011; 17: 2874-2884.
10. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603.
11. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells invitro. Int J Cancer 2012; 133: 247-252.
12. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108: 1334-1338. (Pubitemid 44232033)
13. Hofbauer SW, Pinon JD, Brachtl G, Haginger L, Wang W, Johrer K et al. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells. Cancer Res 2010; 70: 7336-7344.
14. Altman JK, Szilard A, Konicek BW, Iversen PW, Kroczynska B, Glaser H et al. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood 2013; 121: 3675-3681.
15. Altman JK, Glaser H, Sassano A, Joshi S, Ueda T, Watanabe-Fukunaga R et al. Negative regulatory effects of Mnk kinases in the generation of chemotherapyinduced antileukemic responses. Mol Pharmacol 2010; 78: 778-784.
16. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3: 118-131.